**Name of journal: *World Journal of Gastroenterology***

**Manuscript NO: 40338**

**Manuscript Type: EDITORIAL**

**Time to think: Selecting patients who may benefit from synchronous resection of primary pancreatic cancer and liver metastases**

Shi S *et al*. Resection of pancreatic cancer with liver metastasis

Si Shi, Xian-Jun Yu

**Si Shi, Xian-Jun Yu,** Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Shanghai 200032, China

**Si Shi, Xian-Jun Yu,** Department of Oncology, Shanghai Medical College, Fudan University; Shanghai 200032, China

**Si Shi, Xian-Jun Yu,** Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China

**ORCID number:** Si Shi (0000-0002-6652-0629); Xian-Jun Yu (0000-0002-6697-7143).

**Author contributions:** Shi S and Yu XJ conceived the study and drafted the manuscript; both authors approved the final version of the article.

**Supported by** the National Science Foundation for Distinguished Young Scholars of China, No. 81625016 and the Shanghai Sailing Program, No. 17YF1402500.

**Conflict-of-interest statement:** The authors have no conflict of interest to declare.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Xian-Jun Yu, MD, PhD, Professor, Surgeon, Surgical Oncologist,** Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong'an Road, Xuhui District, Shanghai 200032, China. yuxianjun@fudanpci.org

**Telephone:** +86-21-64175590

**Fax:** +86-21-64031446

**Received:** June 16, 2018

**Peer-review started:** June 17, 2018

**First decision:** July 6, 2018

**Revised:** July 11, 2018

**Accepted:** July 22, 2018

**Article in press:**

**Published online:**

**Abstract**

Pancreatic cancer remains a lethal disease and is associated with poor prognosis, particularly for patients with distant metastasis at diagnosis. Recently, Oweira reported a retrospective study that included 13233 metastatic pancreatic cancer patients from the Surveillance, Epidemiology and End Results database. They demonstrated that pancreatic cancer patients with isolated liver metastases had worse outcomes than patients with isolated lung metastases or distant nodal metastases. At present, the standard treatment for metastatic pancreatic cancer is chemotherapy. However, improvement in the safety of pancreatic surgery has led to the consideration of more aggressive surgical approaches. Schneitler reported two cases of hepatic metastatic pancreatic cancer in which negative margin (R0) resection and long survival were achieved after effective preoperative chemotherapy. In general, these two studies indicate that although pancreatic cancer patients with liver metastasis have a poor prognosis, surgical approaches may prolong survival for a few of these patients. A strategy to select hepatic metastatic pancreatic cancer patients who may benefit from surgical intervention is urgently needed.

**Key words:** Pancreatic cancer; Liver metastasis; Chemotherapy; Surgery

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Pancreatic cancer patients with liver metastasis have worse prognoses than pancreatic cancer patients with metastasis at other sites. Improvement in the safety of pancreatic surgery has led to the consideration of more aggressive approaches. There is increasing agreement that synchronous resection of pancreatic cancer and liver metastases may selectively benefit some patients. A prospective multicenter, randomized, controlled phase 3 trial has been launched by the Chinese Study Group for Pancreatic Cancer with a goal of establishing such a selection strategy.

Shi S, Yu XJ. Time to think: Selecting patients who may benefit from synchronous resection of primary pancreatic cancer and liver metastases.*World J Gastroenterol* 2018; In press

**INTRODUCTION**

Pancreatic cancer remains a challenging disease to treat and is associated with a poor prognosis[[1](#_ENREF_1),[2](#_ENREF_2)]. Surgery remains the only curative treatment and provides an opportunity for long-term survival. Unfortunately, however, approximately 50% of pancreatic cancer patients are diagnosed with distant metastases; these patients are then deemed incurable and are generally not considered to be suitable for radical surgeries with curative intent[[3](#_ENREF_3)]. At present, chemotherapy is the standard treatment for patients with metastatic pancreatic cancer. However, improvement in the safety of pancreatic surgery has led to the consideration of more aggressive approaches. Synchronous resection of primary tumors and metastatic sites has continued to be attempted[[4-6](#_ENREF_4)]. Synchronous pancreas and liver resection procedures account for the largest proportion of these attempts. However, most relevant studies have indicated only the safety of such operations, which have failed to produce survival benefits. Nevertheless, there are many case reports demonstrating that certain pancreatic cancer patients can achieve long-term survival after resection of both the primary tumor and liver metastases[[7](#_ENREF_7),[8](#_ENREF_8)].

**STUDY ANALYSIS**

In a recent issue of World Journal of Gastroenterology, Oweira reported a retrospective study performed using data from the Surveillance, Epidemiology and End Results database. A total of 13233 patients with stage IV pancreatic cancer and distant metastases at known sites were included for analysis. Metastatic pancreatic cancer patients were classified according to the site of metastases (liver, lungs, bone, brain or distant lymph nodes). Survival analysis indicated that pancreatic cancer patients with isolated liver metastases had worse outcomes than patients with isolated lung metastases or distant nodal metastases. This research demonstrated that we can reasonably provide different treatment strategies for pancreatic cancer patients with metastases at different sites.

Another interesting study by Schneitler *et al*[9] in *World Journal of Gastroenterology* merits attention. Two cases of hepatic metastatic pancreatic cancer were described in which negative margin (R0) resection and long survival were achieved after a preoperative FOLFIRINOX chemotherapy regimen consisting of 5-FU, folinic acid, irinotecan and oxaliplatin. This study showed that certain pancreatic cancer patients with liver metastasis would benefit from surgical resection after effective chemotherapy.

Taken together, the results of these two studies indicate that although pancreatic cancer patients with liver metastasis generally have a poor prognosis, surgical approaches may prolong survival for a few of these patients. There is increasing agreement that synchronous resection of pancreatic cancer and pancreatic liver metastases should be performed in a highly selective manner in some patients[[10](#_ENREF_10),[11](#_ENREF_11)]. Thus, the determination of how to select for and then treat patients who would benefit from such approaches is urgently required.

**PERSPECTIVE**

In 1995, Hellman and Weichselbaum first proposed the clinically significant condition of oligometastasis, which is a state between local and systemic disease; they advocated for the potential for curative local treatments[[12](#_ENREF_12)]. Further studies have provided evidence to identify distinct biological differences between limited metastatic lesions and widely disseminated disease for multiple tumor types, including pancreatic cancer[[13-15](#_ENREF_13)]. Radical surgery to treat both primary and metastatic sites has been accepted and conducted for an increasing number of tumor types[[16-18](#_ENREF_16)]. Thus, pancreatic cancer patients with few liver metastases may benefit from aggressive surgical approaches. Zanini *et al*[[5](#_ENREF_5)] indicated that the number of liver metastases had a detrimental effect on survival after surgical resection. However, the number of liver metastases alone is insufficient to identify patients who are likely to be surgically cured and achieve improved overall survival (OS).

Chemosensitivity is another important factor that could influence long-term survival and should therefore also be considered and evaluated. Preoperative chemotherapy was more common than direct surgery in previous studies on surgical resection of primary pancreatic cancer for three reasons[[19](#_ENREF_19),[20](#_ENREF_20)]. First, recurrence and new metastases were observed within a short time after surgery and were the main causes of surgical failure[[5](#_ENREF_5)]. Preoperative chemotherapy can inhibit tumor activity and increase both the R0 and negative lymph node (N0) rates[[21](#_ENREF_21)]. Second, the preoperative chemotherapy period can provide an opportunity to verify biological characteristics of cancers and select patients with less aggressive tumors[[22](#_ENREF_22),[23](#_ENREF_23)]. Last, tumor burden may be reduced after preoperative chemotherapy, resulting in decreased surgical difficulty and increased safety.

Another important issue is the time at which to conduct surgical intervention. Although Response Evaluation Criteria In Solid Tumors (RECIST) are commonly employed to evaluate the efficacy of chemotherapy, these criteria are not appropriate for determining the optimal time point for an operation. Carbohydrate antigen 19-9 (CA19-9) is the most commonly used serum tumor marker of pancreatic cancer. It has been reported that CA19-9 response could be used to improve the selection of borderline and locally advanced pancreatic cancer patients who can benefit from resection after primary chemotherapy[[24](#_ENREF_24)]. This conclusion may also be generalized to pancreatic cancer patients with liver metastases. However, approximately 5 to 10% of the population are Lewis-negative individuals; it is known that such individuals exhibit little to no CA19-9 secretion (34, 35). Carbohydrate antigen 125 (CA125) and carcinoembryonic antigen (CEA) are alternative markers because they are the most common serum tumor markers for pancreatic cancer other than CA19-9. In addition, resectability of both the primary tumor and liver metastases should be carefully evaluated before surgical intervention.

Based on the above ideas, the Chinese Study Group for Pancreatic Cancer (CSPAC) has launched a prospective multicenter, randomized, controlled phase 3 trial (NCT03398291) named CSPAC-1. Their goal is to establish a treatment strategy to select patients who can benefit from simultaneous resection of primary pancreatic cancer and liver metastatic sites. The results of this trial are planned to be released in 2025; we are looking forward to their release because they may alter current treatment modes for pancreatic cancer.

**REFERENCES**

1 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* 2018; **68**: 7-30 [PMID: 29313949 DOI: 10.3322/caac.21442]

2 **Chen W**, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. *CA Cancer J Clin* 2016; **66**: 115-132 [PMID: 26808342 DOI: 10.3322/caac.21338]

3 **Mayo SC**, Nathan H, Cameron JL, Olino K, Edil BH, Herman JM, Hirose K, Schulick RD, Choti MA, Wolfgang CL, Pawlik TM. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. *Cancer* 2012; **118**: 2674-2681 [PMID: 21935914 DOI: 10.1002/cncr.26553]

4 **Shrikhande SV**, Kleeff J, Reiser C, Weitz J, Hinz U, Esposito I, Schmidt J, Friess H, Büchler MW. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. *Ann Surg Oncol* 2007; **14**: 118-127 [PMID: 17066229 DOI: 10.1245/s10434-006-9131-8]

5 **Zanini N**, Lombardi R, Masetti M, Giordano M, Landolfo G, Jovine E. Surgery for isolated liver metastases from pancreatic cancer. *Updates Surg* 2015; **67**: 19-25 [PMID: 25702263 DOI: 10.1007/s13304-015-0283-6]

6 **Hackert T**, Niesen W, Hinz U, Tjaden C, Strobel O, Ulrich A, Michalski CW, Büchler MW. Radical surgery of oligometastatic pancreatic cancer. *Eur J Surg Oncol* 2017; **43**: 358-363 [PMID: 27856064 DOI: 10.1016/j.ejso.2016.10.023]

7 **Buc E**, Orry D, Antomarchi O, Gagnière J, Da Ines D, Pezet D. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile? *World J Surg Oncol* 2014; **12**: 347 [PMID: 25407113 DOI: 10.1186/1477-7819-12-347]

8 **Neofytou K**, Giakoustidis A, Smyth EC, Cunningham D, Mudan S. A case of metastatic pancreatic adenocarcinoma with prolonged survival after combination of neoadjuvant FOLFIRINOX therapy and synchronous distal pancreatectomy and hepatectomy. *J Surg Oncol* 2015; **111**: 768-770 [PMID: 25556724 DOI: 10.1002/jso.23867]

9 **Schneitler S**, Kröpil P, Riemer J, Antoch G, Knoefel WT, Häussinger D, Graf D. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection. *World J Gastroenterol* 2015; **21**: 6384-6390 [PMID: 26034375 DOI: 10.3748/wjg.v21.i20.6384]

10 **Nentwich MF**, Bockhorn M, König A, Izbicki JR, Cataldegirmen G. Surgery for advanced and metastatic pancreatic cancer--current state and trends. *Anticancer Res* 2012; **32**: 1999-2002 [PMID: 22593478]

11 **Michalski CW**, Erkan M, Hüser N, Müller MW, Hartel M, Friess H, Kleeff J. Resection of primary pancreatic cancer and liver metastasis: a systematic review. *Dig Surg* 2008; **25**: 473-480 [PMID: 19212120 DOI: 10.1159/000184739]

12 **Hellman S**, Weichselbaum RR. Oligometastases. *J Clin Oncol* 1995; **13**: 8-10 [PMID: 7799047 DOI: 10.1200/JCO.1995.13.1.8]

13 **Wuttig D**, Baier B, Fuessel S, Meinhardt M, Herr A, Hoefling C, Toma M, Grimm MO, Meye A, Rolle A, Wirth MP. Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. *Int J Cancer* 2009; **125**: 474-482 [PMID: 19391132 DOI: 10.1002/ijc.24353]

14 **Lussier YA**, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, Khan SA, Yang X, Hasselle MD, Darga TE, Malik R, Fan H, Perakis S, Filippo M, Corbin K, Lee Y, Posner MC, Chmura SJ, Hellman S, Weichselbaum RR. MicroRNA expression characterizes oligometastasis(es). *PLoS One* 2011; **6**: e28650 [PMID: 22174856 DOI: 10.1371/journal.pone.0028650]

15 **Al-Taee KK**, Ansari S, Hielscher T, Berger MR, Adwan H. Metastasis-related processes show various degrees of activation in different stages of pancreatic cancer rat liver metastasis. *Oncol Res Treat* 2014; **37**: 464-470 [PMID: 25231686 DOI: 10.1159/000365496]

16 **Jin K**, Xu J, Chen J, Chen M, Chen R, Chen Y, Chen Z, Cheng B, Chi Y, Feng ST, Fu D, Hou B, Huang D, Huang H, Huang Q, Li J, Li Y, Liang H, Lin R, Liu A, Liu J, Liu X, Lu M, Luo J, Mai G, Ni Q, Qiu M, Shao C, Shen B, Sheng W, Sun J, Tan C, Tan H, Tang Q, Tang Y, Tian X, Tong D, Wang X, Wang J, Wang J, Wang W, Wang W, Wang Y, Wu Z, Xue L, Yan Q, Yang N, Yang Y, Yang Z, Yin X, Yuan C, Zeng S, Zhang R, Yu X. Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET). *Int J Oncol* 2016; **49**: 1991-2000 [PMID: 27826620 DOI: 10.3892/ijo.2016.3711]

17 **Silberhumer GR**, Paty PB, Denton B, Guillem J, Gonen M, Araujo RLC, Nash GM, Temple LK, Allen PJ, DeMatteo RP, Weiser MR, Wong WD, Jarnagin WR, D'Angelica MI, Fong Y. Long-term oncologic outcomes for simultaneous resection of synchronous metastatic liver and primary colorectal cancer. *Surgery* 2016; **160**: 67-73 [PMID: 27079362 DOI: 10.1016/j.surg.2016.02.029]

18 **Margonis GA**, Buettner S, Sasaki K, Kim Y, Ratti F, Russolillo N, Ferrero A, Berger N, Gamblin TC, Poultsides G, Tran T, Postlewait LM, Maithel S, Michaels AD, Bauer TW, Marques H, Barroso E, Aldrighetti L, Pawlik TM. The role of liver-directed surgery in patients with hepatic metastasis from primary breast cancer: a multi-institutional analysis. *HPB* (Oxford) 2016; **18**: 700-705 [PMID: 27485066 DOI: 10.1016/j.hpb.2016.05.014]

19 **Ma T**, Bai X, Li G, Wei S, Liang T. Neoadjuvant modified-FOLFIRINOX followed by surgical resection of both the primary and metastatic tumors of a pancreatic hepatoid carcinoma with synchronous liver metastasis: A case report. *Medicine* (Baltimore) 2017; **96**: e8413 [PMID: 29069039 DOI: 10.1097/MD.0000000000008413]

20 **Shimura M**, Mizuma M, Hayashi H, Mori A, Tachibana T, Hata T, Iseki M, Takadate T, Ariake K, Maeda S, Ohtsuka H, Sakata N, Morikawa T, Nakagawa K, Naitoh T, Kamei T, Motoi F, Unno M. A long-term survival case treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver metastasis. *Surg Case Rep* 2017; **3**: 132 [PMID: 29285651 DOI: 10.1186/s40792-017-0409-9]

21 **Russo S**, Ammori J, Eads J, Dorth J. The role of neoadjuvant therapy in pancreatic cancer: a review. *Future Oncol* 2016; **12**: 669-685 [PMID: 26880384 DOI: 10.2217/fon.15.335]

22 **Mokdad AA**, Minter RM, Zhu H, Augustine MM, Porembka MR, Wang SC, Yopp AC, Mansour JC, Choti MA, Polanco PM. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. *J Clin Oncol* 2017; **35**: 515-522 [PMID: 27621388 DOI: 10.1200/JCO.2016.68.5081]

23 **Lai TY**, Hu YW. Neoadjuvant Therapy in Resectable Pancreatic Cancer: Immortal Time Bias and Its Correction. *J Clin Oncol* 2017; **35**: 1623 [PMID: 28135147 DOI: 10.1200/JCO.2016.71.2273]

24 **Reni M**, Zanon S, Balzano G, Nobile S, Pircher CC, Chiaravalli M, Passoni P, Arcidiacono PG, Nicoletti R, Crippa S, Slim N, Doglioni C, Falconi M, Gianni L. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. *Ann Oncol* 2017; **28**: 2786-2792 [PMID: 28945895 DOI: 10.1093/annonc/mdx495]

**P-Reviewer:** He SQ, Polistina FA **S-Editor:** Wang XJ

**L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0